Skip to Content

Proteostasis Therapeutics, Inc.

Company NameProteostasis Therapeutics, Inc.
Stock SymbolPTI

On March 20, 2018, Kerrisdale Capital Management LLC published a report claiming that the Company’s claimed success of its Phase 2 proof-of-concept trial of PTI-428 “stems almost entirely from the anomalously bad performance of the 4-person placebo group, while, on average, patients taking PTI-428 barely improved.” The report also claimed that “Proteostasis has a habit of sweeping unpleasant or confusing findings under the rug.” On this news, shares of Proteostasis fell $1.83, or 26%, to close at $5.16 on March 20, 2018, thereby injuring investors.

Submit Your Information

If you suffered a loss on your Proteostasis Therapeutics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd